Clinical and Medical Case Reports

ISSN: 2684-4915

Open Access

Articles in press and Articles in process

    Review Pages: 1 - 1

    Potential Therapeutic Role of Estradiol Agonists and Androgen Antagonists in COVID-19

    Melissa Suma and Haibo Zhang

    Epidemiological data from the COVID-19 pandemic shows increased severity and mortality among males compared with females. Several studies offer evidence that this disparity may be, in part, due to sex hormone biases contributing to different outcome in SARS-CoV-2, suggesting hormone therapy as a potential combination treatment alongside antivirals in COVID-19. This review explores the potential mechanisms by which estrogen and androgen have distinct impact on the development of COVID-19.

    Case Series Pages: 1 - 7

    INOSITOLIC DERIVATIVES COMBINED WITH PRORESOLUTIVE LIPID MEDIATORS: preliminary results in the first-line treatment of patients with polycystic ovary syndrome .

    Garcia Manero Manuel, Ceamanos Montanes Carolina, Campo Ainhoa, Peru Gema

    Objective: To evaluate the effect of the combination of inositolic derivatives and lipid mediators on the metabolic and inflammatory profile of women with polycystic ovary syndrome. Material and methods: Experimental, prospective and longitudinal study carried out in patients diagnosed with polycystic ovary syndrome (Rotterdam criteria) without treatment or previous dietary intervention. The following nutritional preparations were administered orally daily: Group A: 300mg D-chiro-inositol, 1099mg myo- inositol + 30mg lipinova Group B: 4000 mg of myo-inositol + 30 mg of lipinova The metabolic profile is compared before and after 4 weeks of treatment in each patient, determining the insulin levels and the HOMA index. The inflammatory profile was analyzed by determining the levels of IL-6 before and after treatment. Results: 41 patients with polycystic ovary syndrome subdivided into 20 from group A and 21 from group B were studied. Insulin levels before and after treatment was 17.9 ± 9.3 SD and 10 ± 4.09 SD, respectively, with statistically significant differences. The HOMA index pre-treatment was 4.1 ± 2.1 SD and 2.1 ± 1.1 SD post-treatment, with significant differences the level of IL-6 was pretreatment was 3.8 ± 1.5 Sd of 2.1 ± 1.09 post treatment with significant differences. Conclusion: The results of the study show the positive effect of the combined administration of inositolic derivatives and pro-resolution lipid mediators on the metabolic, clinical and inflammatory profile of patients with polycystic ovary syndrome.

Relevant Topics

arrow_upward arrow_upward